18:33 , Oct 19, 2018 |  BC Week In Review  |  Company News

SQZ, Roche expand deal to jointly develop cancer cell therapies

SQZ Biotechnologies Co. (Watertown, Mass.) and Roche (SIX:ROG; OTCQX:RHHBY) expanded a 2015 deal to co-develop and commercialize antigen presenting cell (APC) therapies to treat cancers that are difficult to address with other adoptive cell therapy...
18:39 , Oct 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Patient sample and mouse studies suggest T cell-specific inhibition of XBP1 or IRE1 could help treat ovarian cancer. In tumor and ascites samples from patients, high T cell expression of XBP1 was...
22:51 , Oct 17, 2018 |  BC Extra  |  Preclinical News

Immune-Onc, University of Texas discover new AML target

A study published Wednesday in Nature revealed a checkpoint inhibitor target for acute myelogenous leukemia, adding a new mechanism of action for an indication that, until recently, has been a new drug wasteland. Immune-Onc Therapeutics...
14:41 , Oct 15, 2018 |  BC Extra  |  Company News

SQZ, Roche expand deal to jointly develop cancer cell therapies

SQZ Biotechnologies Co. (Watertown, Mass.) and Roche (SIX:ROG; OTCQX:RHHBY) expanded a 2015 deal to co-develop and commercialize antigen presenting cell (APC) therapies to treat cancers that are difficult to address with other adoptive cell therapy...
22:57 , Oct 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer; infectious disease

INDICATION: Brain cancer; colorectal cancer; viral infection Mouse studies suggest inhibiting HPK1 kinase activity alone or in combination with PD-L1 inhibitors could help treat brain cancer, colorectal cancer and lymphocytic choriomeningitis virus (LCMV) infection. In mouse...
21:52 , Oct 5, 2018 |  BC Extra  |  Preclinical News

Selecta's rapamycin nanoparticles could enable re-dosing of gene therapies

Selecta Biosciences Inc. (NASDAQ:SELB) showed its SVP-Rapamycin nanoparticles co-administered with an adeno-associated viral (AAV) vector-mediated transgene could enable repeat dosing of a gene therapy by suppressing the host’s immune response against the viral vector in...
18:32 , Sep 28, 2018 |  BioCentury  |  Emerging Company Profile

Stopping chain swapping

By controlling how antibody chains pair, Elstar Therapeutics Inc.’s platform can produce multispecific antibodies at yields comparable to methods for manufacturing monospecific antibodies. The company develops multispecific antibodies with up to four functional domains that bind...
17:37 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Transplant

INDICATION: Graft-versus-host disease (GvHD); organ transplant rejection; renal transplant rejection Mouse and non-human primate studies suggest inhibiting CD122 could enhance the efficacy of Nulojix belatacept to treat GvHD, skin graft rejection and renal transplant rejection. In...
20:42 , Sep 13, 2018 |  BC Innovations  |  Emerging Company Profile

Mapping tumor markers

BioGraph 55 Inc. is mapping immune cells in the tumor microenvironment to identify cell-to-cell interaction patterns that can help match patients to existing therapies and identify novel therapeutic targets. The newco is developing a pipeline...
19:27 , Sep 10, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens; other

TECHNOLOGY: Cellular assays; computational models An algorithm based on cytometric data from multiple studies could help identify cell populations as diagnostic or prognostic markers of disease. The algorithm involves three steps. First, it processes raw...